- Home
- OXM vs DNTH Comparison
OXM vs DNTH Comparison
Compare OXM & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXM
- DNTH
- Stock Information
- Founded
- OXM 1942
- DNTH 2015
- Country
- OXM United States
- DNTH United States
- Employees
- OXM N/A
- DNTH N/A
- Industry
- OXM Apparel
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- OXM Consumer Discretionary
- DNTH Health Care
- Exchange
- OXM Nasdaq
- DNTH Nasdaq
- Market Cap
- OXM 672.2M
- DNTH 606.2M
- IPO Year
- OXM N/A
- DNTH N/A
- Fundamental
- Price
- OXM $36.98
- DNTH $20.59
- Analyst Decision
- OXM Hold
- DNTH Strong Buy
- Analyst Count
- OXM 6
- DNTH 8
- Target Price
- OXM $55.80
- DNTH $53.00
- AVG Volume (30 Days)
- OXM 391.8K
- DNTH 371.4K
- Earning Date
- OXM 09-10-2025
- DNTH 08-11-2025
- Dividend Yield
- OXM 7.47%
- DNTH N/A
- EPS Growth
- OXM 100.54
- DNTH N/A
- EPS
- OXM 5.14
- DNTH N/A
- Revenue
- OXM $1,511,278,000.00
- DNTH $6,524,000.00
- Revenue This Year
- OXM $0.49
- DNTH N/A
- Revenue Next Year
- OXM $1.90
- DNTH N/A
- P/E Ratio
- OXM $7.20
- DNTH N/A
- Revenue Growth
- OXM N/A
- DNTH 102.36
- 52 Week Low
- OXM $36.25
- DNTH $13.37
- 52 Week High
- OXM $105.84
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- OXM 34.42
- DNTH 52.74
- Support Level
- OXM $41.05
- DNTH $21.27
- Resistance Level
- OXM $44.46
- DNTH $23.21
- Average True Range (ATR)
- OXM 2.13
- DNTH 1.25
- MACD
- OXM -0.54
- DNTH -0.07
- Stochastic Oscillator
- OXM 7.16
- DNTH 39.77
About OXM Oxford Industries Inc.
Oxford Industries Inc is an apparel manufacturing company that designs, sources, markets, and distributes products under the brand name Tommy Bahama, and Lilly Pulitzer. Tommy Bahama designs, sources, markets, and distributes men's and women's sportswear and related products. Lilly Pulitzer designs, sources, markets, and distributes upscale collections of women's and women's dresses, sportswear, and related products. The company generates majority of its revenue from the Tommy Bahama division.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.